Allucent Recognized with CRO Leadership Awards for Expertise and Compatibility
"We're honored to be recognized through the CRO Leadership Awards for the second consecutive year," said
To determine the award winners, 42 contract research organizations were assessed on more than 20 performance metrics through ISR's annual CRO Quality Benchmarking survey. Survey respondents were recruited from biopharmaceutical companies of all sizes and have decision-making authority at their companies when working with CROs. Individuals completing the survey evaluated companies with whom they had outsourced a project in the past 18 months to ensure the data determining the award winners reflect first-hand experience working with the CROs being evaluated.
About Allucent
Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of its biopharma and government clients. Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across various therapeutic areas. With more than 30 years of experience in over 60 countries, Allucent's individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients. Visit Allucent.com for more information.
View original content to download multimedia:https://www.prnewswire.com/news-releases/allucent-recognized-with-cro-leadership-awards-for-expertise-and-compatibility-302134854.html
SOURCE Allucent
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Howard Hughes Holdings Set to Join S&P SmallCap 600
- The Stash Room to Host Veterans Day Bash with Balanced Veterans Network and Operation 1620
- Pepe Coin Price Prediction: PEPE Pulls Back Near $0.00000443 as Remittix’s $33M Raise Sharpens the Early-Entry Debate
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share